Hoffmann-La Roche
Sefaxersen (RO7434656)
Primary IgA Nephropathy
Countdown
55days
Phase 3 readout · Aug 31, 2026
What's at stake
Phase 3 trial results for Sefaxersen (RO7434656) in Primary IgA Nephropathy are due Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 18h ago
“CT.gov NCT05797610: Phase 3 trial, sponsor Hoffmann-La Roche, drug Sefaxersen (RO7434656). Primary completion date 2026-08-31 (estimated).”